Coronavirus (COVID-19) News
Filter News
Found 2,554 articles
-
Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
11/10/2022
After the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by the European Commission, as a booster for the prevention of COVID-19 in adults 18 years of age and older.
-
Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV
11/8/2022
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its primary vaccination Phase II study in the Philippines and heterologous booster vaccination Phase II study in United Arab Emirates in respect of its recombinant COVID-19 vaccine ReCOV.
-
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
11/4/2022
Pfizer Inc. and BioNTech SE announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.
-
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19
11/3/2022
Biophytis SA released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.
-
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
11/2/2022
CytoSorbents Corporation announced the presentation of the final key results from the U.S. multicenter CytoSorb Therapy in COVID-19 Registry at the 35th Annual Congress of the European Society of Intensive Care Medicine in Paris last week.
-
The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature
11/2/2022
The Access to Advanced Health Institute announced results from a study of their new RNA vaccine against COVID-19.
-
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
11/1/2022
Moderna, Inc. announced that it has received approval from the Ministry of Health, Labour and Welfare in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.222 in adults 18 years and older.
-
ScreenPro Reports a Major Increase in Positive Test Results
10/28/2022
ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) ("ScreenPro" or the "Company") would like to share an internal report indicating the Company's Covid PCR (Polymerase Chain Reaction) testing has experienced a significant spike in positivity rates in their testing results in the film and production industry.
-
Canadian Cardiovascular Society Receives $1.6 million to Study Myocarditis and/or Pericarditis after mRNA COVID-19 Vaccination
10/27/2022
Dr. Howard Njoo, Canada's Deputy Chief Public Health Officer and Interim Vice-President of the Infectious Diseases Programs Branch, announced funding to support a pan-Canadian study of the clinical and functional outcomes of adults and children who experienced myocarditis and/or pericarditis after receiving an mRNA COVID-19 vaccination.
-
Pandemic Protect Deployed in Massachusetts as COVID-19 Cases Rise
10/27/2022
Quantgene, a medical intelligence firm specializing in precision medicine and advanced COVID-19 solutions, is now offering Pandemic Protect throughout Massachusetts as COVID-19 cases rise.
-
Therma Bright Receives New Billing Codes for Venowave Allowing for Reimbursement from Medicare, Medicaid, and Private Insurers
10/27/2022
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies
-
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
10/26/2022
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced it has completed enrollment for the second cohort of a three cohort Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection.
-
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
10/26/2022
Bristol Myers Squibb announced new retrospective analyses on serologic responses and clinical outcomes with COVID-19 vaccination in participants treated with Zeposia from the ongoing Phase 3 DAYBREAK open-label extension study in relapsing multiple sclerosis.
-
Early Data Indicate Gritstone’s Self-Amplifying mRNA Vaccine could Fill COVID-19 Gaps - Updated
10/25/2022
Data from two Phase I trials indicate Gritstone Bio's samRNA vaccine can safely induce a strong and durable immune response against COVID-19. -
Inotrem Announces That Its ESSENTIAL Phase II Study for the Treatment of Critically ill COVID-19 Patients Meets Its Primary and Key Secondary Endpoints
10/25/2022
Inotrem announced at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positive results for ESSENTIAL, its Phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress.
-
Understanding the Evolution of SARS-CoV-2 Could Be the Key to Treating It, According to Researchers at the UCSF QBI Coronavirus Research Group (QCRG)
10/25/2022
Researchers at the UCSF QBI Coronavirus Research Group have uncovered how the SARS-CoV-2 variants of concern differ in their ability to manipulate human cells on a molecular level during infection.
-
Naltrexone Demonstrates Promising Long COVID Application
10/20/2022
LOVE Pharma Co., the Company having announced its nonbinding Letter of Intent to acquire Naltrexone Therapeutics Inc., on October 11th, is pleased to share that Naltrexone has been identified to show promise in treatment of long COVID.
-
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
10/19/2022
Moderna, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization for mRNA-1273.222 as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, who have previously received at least a primary vaccination course against COVID-19.
-
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
10/19/2022
Moderna, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending a variation to the conditional marketing authorization to include a 25 µg two-dose series of Spikevax for active immunization to prevent coronavirus disease 2019 caused by SARS-CoV-2 in children 6 months to 5 years.
-
bioLytical Laboratories Inc. receives WHO PQ for its iStatis COVID-19 Antigen Home Test
10/18/2022
bioLytical Laboratories Inc., a global leader in rapid in-vitro medical diagnostics, announced it has received its WHO PQ for its self-test, the iStatis COVID-19 Antigen Home Test, allowing its immediate entry into international markets.